Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioscience
Ym Biosciences Subsidiary Cimym Notifies Oncoscience Ag of Intention To Submit Issues for Arbitration
December 6th, 2008
YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, announced that CIMYM BioSciences Inc., a corporation owned by YM and CIMAB S.A., has notified Oncoscience AG, the licensee for its drug, nimotuzumab, that it intends to submit issues for arbitration to the London Court of International Arbitration (LCIA). This arbitration will be conducted through the LCIA based in London, using a single arbitrator to be appointed by the parties or, failing agreement, by the LCIA. "Our action is based on our position that Oncoscience AG, in addition to a number of...
Source: Law & Health Weekly (2008-12-06)
|
